Hexarelin: The Complete Guide

Hexarelin occupies a strange position in the peptide space. It is, by most measures, the most potent growth hormone releasing peptide ever developed. In human studies, it produced dose-dependent GH surges that exceeded those of GHRH itself, peaking at roughly 55 ng/mL within 30 minutes of administration. And yet, it was never approved, never marketed, and its clinical development was abandoned in 2005.

The story of hexarelin is the story of a compound that turned out to be more interesting than anyone initially expected. Researchers at Tulane and later in Italy designed it in the early 1990s as an optimized growth hormone secretagogue. What they got was a peptide that not only released growth hormone with unmatched potency but also protected the heart through a completely separate receptor system that no one knew existed at the time.

Three decades and hundreds of published studies later, hexarelin remains one of the most pharmacologically fascinating peptides in the GHRP family. It reached Phase 2 clinical trials for both GH deficiency and congestive heart failure. Its cardioprotective effects, mediated through the CD36 scavenger receptor rather than through growth hormone, represent a mechanism of action that is unique among all growth hormone secretagogues. And its desensitization profile, which ultimately limited its clinical development, has taught us a great deal about how the ghrelin receptor system actually works.

This guide covers the mechanism, the evidence, the practical details, and the honest limitations of hexarelin.

What Hexarelin Is

Hexarelin (also known as examorelin) is a synthetic hexapeptide with the amino acid sequence His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2. It belongs to the growth hormone releasing peptide (GHRP) family, a class of compounds derived from structural modifications to met-enkephalin that were found to stimulate growth hormone secretion through a receptor distinct from GHRH.

It was specifically designed to maximize GH-releasing potency while improving metabolic stability. Compared to its predecessor GHRP-6, hexarelin is more resistant to enzymatic degradation and produces a stronger growth hormone response per unit dose. Its molecular weight is 887.06 Da, and it has a plasma half-life of approximately 60 to 80 minutes following subcutaneous injection.

Hexarelin does not occur naturally. It is a synthetic analog that mimics certain actions of ghrelin, the endogenous 28-amino-acid hormone discovered in 1999, though hexarelin was developed a decade before ghrelin was even identified. This is one of those unusual cases in pharmacology where the synthetic tool came first, the receptor was cloned second, and the natural hormone was found last.

The Dual Mechanism: Two Receptors, Two Stories

What makes hexarelin genuinely unusual among growth hormone secretagogues is that it acts through two entirely separate receptor systems. Most GHRPs operate primarily through the ghrelin receptor (GHS-R1a). Hexarelin does this too, but it also binds with high affinity to CD36, a scavenger receptor found predominantly in cardiac tissue. These two mechanisms produce fundamentally different effects, and understanding both is essential to understanding hexarelin.

This dual mechanism was discovered through an elegant series of experiments. Clinicians first noticed that patients receiving hexarelin for heart failure showed cardiac improvements even after their GH response had desensitized. That clinical observation led researchers at the University of Montreal to systematically identify CD36 as the cardiac binding target. They labeled rat cardiac membranes with a radioactive hexarelin derivative and purified the binding protein, identifying it as CD36.

This finding fundamentally changed how researchers thought about hexarelin. It was no longer just a potent GH releaser with some incidental cardiac effects. It was a compound that happened to interact with two completely separate biological systems, producing two distinct therapeutic profiles.

Growth Hormone Release: The Evidence

The foundational human pharmacology study for hexarelin was published by Imbimbo and colleagues in the European Journal of Clinical Pharmacology in 1994. The study was a double-blind, placebo-controlled dose-response trial in healthy subjects receiving intravenous hexarelin at 0.5, 1.0, and 2.0 mcg/kg.

The results showed a clear dose-dependent pattern. GH peaked at approximately 30 minutes after administration and returned to baseline within 240 minutes. At the 2 mcg/kg dose, the response was near the ceiling of what hexarelin could produce, with a Cmax of 55.0 ng/mL versus 3.9 ng/mL for placebo. Importantly, hexarelin did not affect plasma glucose, LH, FSH, or TSH, indicating specificity for the GH axis with minimal disruption to other pituitary hormones.

However, hexarelin is not perfectly selective. Arvat and colleagues at the University of Turin published a comparative study in Peptides (1997) showing that hexarelin, like GHRP-2, produces mild but measurable increases in prolactin, ACTH, and cortisol. Their data placed hexarelin's prolactin-stimulating effect below that of TRH, while its ACTH/cortisol-stimulating effect was comparable to that of human CRH.

A separate finding of note: in elderly subjects (ages 66-73), hexarelin still produced strong GH responses comparable to those in younger adults. This age-independence is noteworthy because natural GH secretion and GHRH responsiveness both decline significantly with age.

The Cardioprotective Evidence

The cardiac research on hexarelin is the most scientifically compelling aspect of this compound. It has been studied in multiple animal models of heart disease, including ischemia-reperfusion injury, myocardial infarction, cardiac fibrosis, and atherosclerosis. The consistency of the results across these models is striking.

Ischemia-Reperfusion Injury

In 1999, Locatelli and colleagues published a landmark study in Endocrinology demonstrating that hexarelin's cardioprotective effects are independent of growth hormone. They compared hexarelin and GH treatment in hypophysectomized rats (animals with no pituitary gland and thus no ability to produce GH). After seven days of treatment, the rats' hearts were subjected to ischemia and reperfusion.

A later study by Rossoni and colleagues compared hexarelin to equimolar ghrelin in hypophysectomized rats. Hexarelin was far more effective: it provided 60% protection against left ventricular end-diastolic pressure increases, versus only 15% for ghrelin. Creatine kinase release (a marker of cardiac cell death) was reduced by 55% with hexarelin versus 15% with ghrelin.

Myocardial Infarction Model (2020)

The most clinically relevant cardiac study was published in 2020. Ma and colleagues used a mouse model of myocardial ischemia-reperfusion, ligating the left coronary artery and then allowing reperfusion, mimicking what happens during a heart attack and subsequent treatment. Hexarelin was administered at 0.3 mg/kg/day for 21 days, starting immediately before reperfusion.

Anti-Atherosclerotic Effects

Hexarelin's interaction with CD36 on macrophages also has implications for atherosclerosis. In macrophage cell models, hexarelin reduced the uptake of oxidized LDL through CD36, which is a key step in foam cell formation within atherosclerotic plaques. A study by Pang and colleagues in Peptides (2010) showed that hexarelin treatment in atherosclerotic rats suppressed plaque formation, partially reversed unfavorable HDL/LDL ratios, and increased nitric oxide production and endothelial nitric oxide synthase expression.

The Desensitization Problem

This is the single biggest limitation of hexarelin, and it is what ultimately ended its clinical development. Repeated daily administration produces progressive attenuation of the GH response, with significant blunting evident within one to two weeks of continuous use.

Rahim and Shalet published a study in the Journal of Clinical Endocrinology and Metabolism (1998) examining long-term hexarelin therapy. Over 16 weeks of treatment, they observed a marked decrease in participants' GH responsiveness. However, after a four-week washout period, sensitivity partially recovered, returning to near-baseline levels.

The mechanisms behind this desensitization are multiple and concurrent. They include GHS-R1a receptor downregulation through ligand-induced internalization (the receptor literally pulls itself off the cell surface), increased hypothalamic somatostatin tone (the body's natural GH brake), and negative feedback through elevated IGF-1 levels. In vitro work by Orkin and colleagues (2003) showed that calcium response desensitization at the GHS receptor occurred within 2 to 5 minutes of the first hexarelin exposure, confirming that receptor-level desensitization is rapid and intrinsic.

Hexarelin vs. Other GHRPs: A Comparison

The GHRP family includes several well-studied compounds. Each has a different profile of potency, selectivity, and side effects. Hexarelin sits at the high-potency, lower-selectivity end of the spectrum, while ipamorelin occupies the opposite position.

Property	Hexarelin	GHRP-2	GHRP-6	Ipamorelin
GH potency	Highest	High	Moderate	Moderate
Prolactin elevation	Mild	Mild-Moderate	Mild	None
Cortisol/ACTH elevation	Mild	Mild-Moderate	Mild-Moderate	None
Hunger stimulation	Minimal	Moderate	Strong	Minimal
Desensitization	Significant (1-2 wks)	Moderate	Moderate	Mild
CD36/Cardiac effects	Yes (unique)	No	No	No
Bone growth	Via GH/IGF-1	Via GH/IGF-1	Via GH/IGF-1	Direct (4x deposition)
Half-life	~60-80 min	~60 min	~25 min	~2 hours
Clinical development	Phase 2 (discontinued)	Phase 2	Phase 2	Phase 2

Dosing Protocols

The published human pharmacology data and practitioner protocols converge on a fairly consistent dosing framework. The key principles are: start low, divide doses across the day, administer on an empty stomach, and cycle strictly.

The bell-shaped dose-response curve means that escalating beyond 2 mcg/kg (roughly 140-200 mcg for most adults) per injection does not produce proportionally greater GH release. The Imbimbo data showed that 2 mcg/kg was already near the maximum effective dose. More is not better with hexarelin.

Synergistic Stacking

When combined with a GHRH analog (such as CJC-1295 without DAC or sermorelin), hexarelin produces synergistic GH release. The mechanism behind this synergy is well understood: GHRPs like hexarelin suppress somatostatin (the GH brake) and increase per-cell GH output, while GHRH increases the number of somatotroph cells that are actively secreting. Together, these produce GH surges that exceed what either compound produces alone.

Side Effects and Safety

Hexarelin demonstrated acceptable safety in Phase 2 clinical trials. No serious adverse events were reported in the published human studies. However, its side effect profile is broader than more selective GHRPs like ipamorelin.

Side Effect	Frequency	Mechanism	Notes
Mild cortisol elevation	Common	ACTH stimulation via GHS-R1a	Comparable to physiological CRH response
Prolactin increase	Common (mild)	Pituitary stimulation	Lower than TRH-induced elevation
Water retention	Common	GH-mediated fluid shifts	Typically transient, resolves within weeks
Injection site reactions	Occasional	Local irritation	Minimized by rotating sites
Tingling/numbness in hands	Occasional	GH-related (carpal tunnel-like)	Dose-dependent, resolves with dose reduction
Increased appetite	Mild/occasional	Ghrelin receptor activation	Much less than GHRP-6
GH response desensitization	Expected	Receptor downregulation	Reversible with 4-6 week washout

What to Expect: A Realistic Timeline

The Bottom Line

Hexarelin is a compound that rewards close reading. On the surface, it looks like just another GHRP in a crowded category. Under the surface, it is a dual-mechanism peptide with the strongest acute GH-releasing potency in its class and a unique cardiac protective profile that operates through a completely separate receptor system.

Its limitations are real. The desensitization problem makes it impractical for continuous, long-term GH therapy. Its off-target effects on cortisol and prolactin, while mild, make it less clean than ipamorelin for uncomplicated GH protocols. It was never approved, and its clinical development ended without resolution.

But its strengths are equally real. The CD36-mediated cardioprotective effects are not shared by any other GHRP. The preclinical cardiac data, spanning from the Locatelli ischemia-reperfusion studies in 1999 through the Ma ischemia-reperfusion MRI study in 2020, is both consistent and impressive. The synergistic response when combined with GHRH analogs is potent. And its ability to produce strong GH responses even in elderly subjects suggests utility in populations where age-related GH decline is most clinically relevant.

For short-cycle, high-intensity GH protocols or for anyone interested in the cardiac protective angle, hexarelin remains one of the most scientifically well-supported peptides available. For long-term, maintenance-level GH support, there are better options. Understanding which situation you are in determines whether hexarelin belongs in your protocol.